Zymeworks Files Automatic Shelf Registration Statement and Enters into At-The-Market Equity Offering Sales Agreement
05 Novembro 2019 - 8:00PM
Business Wire
Zymeworks Inc. (NYSE: ZYME), a clinical‑stage biopharmaceutical
company developing multifunctional therapeutics, announced today
that it has filed an automatic shelf registration statement on Form
S-3 (the “Registration Statement”) with the Securities and
Exchange Commission (the “SEC”) to replace its existing
shelf registration statement on Form S-3. Zymeworks has become a
“well-known seasoned issuer” (“WKSI”) under SEC rules and is
filing the new Registration Statement to take advantage of certain
benefits only available to WKSIs.
The Registration Statement will enable Zymeworks to issue and
sell its securities in one or more future offerings. The specific
terms of any offering will be established by Zymeworks at the time
of the offering, subject to market conditions, and will be
described in detail in a prospectus supplement filed at the time of
such offering.
Concurrent with the filing of the Registration Statement,
Zymeworks has also entered into an Open Market Sale AgreementSM
(the “ATM Sales Agreement”) with Jefferies LLC, effective as
of November 5, 2019. Under the ATM Sales Agreement, Zymeworks may
sell its common shares from time to time for up to US$75.0 million
in aggregate sales proceeds in “at-the-market” transactions. Before
you invest in the securities offered, you should read the
prospectus supplement relating to and describing the terms of the
offering and the related Registration Statement and other documents
that Zymeworks has filed with the SEC for more complete information
about Zymeworks and the offering. You may get these documents for
free by visiting EDGAR on the SEC website at www.sec.gov.
Alternatively, copies of the prospectus supplement relating to the
offering may be obtained, when available, from: Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, New York, New York 10022, telephone: 1-877-821-7388 or by
emailing Prospectus_Department@jefferies.com.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities being offered, nor
may there be any sale of the securities being offered in any state
or other jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any state or other jurisdiction.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company
dedicated to the development of next-generation multifunctional
biotherapeutics. Zymeworks’ suite of therapeutic platforms and its
fully integrated drug development engine enable precise engineering
of highly differentiated product candidates. Zymeworks’ lead
clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody
currently in Phase 2 clinical development. Zymeworks’ second
clinical candidate, ZW49, is a bispecific antibody-drug conjugate
currently in Phase 1 clinical development and combines the unique
design and antibody framework of ZW25 with Zymeworks’ proprietary
ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep
preclinical pipeline in immuno-oncology and other therapeutic
areas. In addition, its therapeutic platforms are being leveraged
through strategic partnerships with nine biopharmaceutical
companies.
Cautionary Note Regarding Zymeworks’ Forward Looking
Statements
This press release includes “forward-looking statements” within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995 and “forward-looking information” within the meaning of
Canadian securities laws, or collectively, forward-looking
statements. Forward-looking statements in this news release
include, but are not limited to, statements regarding our
expectations regarding our offering from time to time of common
shares pursuant to the at-the-market equity offering sales
agreement, and other information that is not historical
information. When used herein, words and phrases such as “enable”,
“advance”, “believe”, initiate”, “may”, “plan”, “will”, “estimate”,
“continue”, “anticipate”, “intend”, “except” and similar
expressions are intended to identify forward-looking statements. In
addition, any statements or information that refer to expectations,
beliefs, plans, projections, objectives, performance or other
characterizations of future events or circumstances, including any
underlying assumptions, are forward-looking. All forward-looking
statements are based upon Zymeworks’ current expectations and
various assumptions. Zymeworks believes there is a reasonable basis
for its expectations and beliefs, but they are inherently
uncertain. Zymeworks may not realize its expectations, and its
beliefs may not prove correct. Actual results could differ
materially from those described or implied by such forward-looking
statements as a result of various factors, including, without
limitation, market conditions and the factors described under “Risk
Factors” in the prospectus supplement and Zymeworks’ Quarterly
Report on Form 10-Q for the nine month period ended September 30,
2019 (a copy of which may be obtained at www.sec.gov and
www.sedar.com). Consequently, forward-looking statements should be
regarded solely as Zymeworks’ current plans, estimates and beliefs.
Investors should not place undue reliance on forward-looking
statements. Zymeworks cannot guarantee future results, events,
levels of activity, performance or achievements. Zymeworks does not
undertake and specifically declines any obligation to update,
republish, or revise any forward-looking statements to reflect new
information, future events or circumstances, or to reflect the
occurrences of unanticipated events, except as may be required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191105006112/en/
Zymeworks Inc. Investor Inquiries: Ryan Dercho, Ph.D.
(604) 678-1388 ir@zymeworks.com
Tiffany Tolmie (604) 678-1388 ir@zymeworks.com
Media Inquiries: Kavita Shah, Ph.D. (604) 678-1388
info@zymeworks.com
Zymeworks (NYSE:ZYME)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Zymeworks (NYSE:ZYME)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024